Insider Selling: Santarus SVP Sells 17,100 Shares of Stock (SNTS)
Santarus (NASDAQ:SNTS) SVP Carey Fox sold 17,100 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $21.91, for a total transaction of $374,661.00. Following the sale, the senior vice president now directly owns 24,567 shares of the company’s stock, valued at approximately $538,263. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Santarus (NASDAQ:SNTS) traded down 3.79% on Tuesday, hitting $21.05. 2,068,050 shares of the company’s stock traded hands. Santarus has a one year low of $8.47 and a one year high of $28.10. The stock’s 50-day moving average is $22.78 and its 200-day moving average is $21.79. The company has a market cap of $1.397 billion and a P/E ratio of 15.25.
Santarus (NASDAQ:SNTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.94 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter last year, the company posted $0.05 earnings per share. Santarus’s revenue was up 89.4% compared to the same quarter last year. Analysts expect that Santarus will post $1.26 EPS for the current fiscal year.
SNTS has been the subject of a number of recent research reports. Analysts at Ned Davis Research initiated coverage on shares of Santarus in a research note to investors on Monday. They set a “neutral” rating on the stock. Separately, analysts at Leerink Swann downgraded shares of Santarus from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, August 22nd. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at JMP Securities raised their price target on shares of Santarus from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $25.63.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.